Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.27 which represents a slight increase of $0.53 or 0.90% from the prior close of $58.74. The stock opened at ...

Discover why Bristol-Myers Squibb's stock price has risen 25% in six months and why it's rated a 'Buy' with a 4% dividend ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

(Photo by Marla Aufmuth/Getty Images for Pennsylvania Conference For Women ) Barring the recent rise, BMY stock hasn’t fared well, with an 11% decline since January 2023 — falling from levels ...

Leerink Partners analyst David Risinger has maintained their bullish stance on BMY stock, giving a Buy rating on November 19.Don't Miss our ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Shareholder Yield Investor model based on the ...

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.